B19.0

Thiamine

Thiamine (Vitamin B1)

An essential B vitamin critical for carbohydrate metabolism, nerve function, and energy production in the brain and muscles.

bodymentalvitaminenergyneurologicalessential
Last reviewed: February 1, 2025
9.0/10
40+ studies
Evidence
high
Safety
50-100mg daily; 150-600mg benfotiamine for neuropathy
Dose
4-12 weeks
Time to Effect
Benfotiamine (fat-soluble, higher bioavailability)
Best Form

Thiamine (Vitamin B1) was the first B vitamin discovered and is essential for converting carbohydrates into energy. It's particularly important for nervous system function and is required for the synthesis of acetylcholine. Deficiency causes beriberi and Wernicke-Korsakoff syndrome. Benfotiamine, a fat-soluble form, has enhanced bioavailability and is used for neuropathy and advanced glycation protection.

Mechanisms of Action

🔥
Carbohydrate Metabolism

Converts carbs to usable energy

⚡
Nerve Function

Essential for nerve signal transmission

🛡️
AGE Protection (Benfotiamine)

Reduces advanced glycation end products

Recommended Dose

50-100mg daily; 150-600mg benfotiamine for neuropathy

25mg500mg

Loading: Not typically required

Optimal Timing

  • With food
  • Morning with other B vitamins

Take with food

Best Form

Benfotiamine (fat-soluble, higher bioavailability)

Alternatives: Thiamine HCl (standard), Thiamine Mononitrate, Sulbutiamine (crosses BBB)

Benfotiamine is preferred for neuropathy and AGE protection. Sulbutiamine has nootropic effects but may require cycling.

Duration

Minimum: 4 weeks

Optimal: 12 weeks

Cycling: Not required

Note: Standard thiamine is water-soluble. Benfotiamine is fat-soluble and should be taken with a meal containing fat.

Personalized Dosage Calculator

Get a dosage recommendation tailored to your body weight, age, goals, and health profile.

Set up your health profile for personalized recommendations

⚡
Energy Production

Improved energy from food metabolism

2-4 weeks
60% of users notice thispositive
🧠
Nerve Support

Supports healthy nerve function

4-8 weeks
55% of users notice thispositive
🦶
Neuropathy Relief (Benfotiamine)

May reduce diabetic neuropathy symptoms

4-12 weeks
65% of users notice thispositive
High SafetyMax safe dose: No toxicity established; excess excreted in urine
🟡
Diabetics

Benfotiamine well-studied for diabetic neuropathy protection

🟡
Heavy alcohol users

Higher doses often needed; alcohol depletes thiamine

Who Should NOT Take This

  • Known allergy or hypersensitivity to Thiamine or related compounds

Drug Interactions

Loop diuretics (furosemide)mild

May increase thiamine excretion

Digoxinmild

Thiamine may help improve digoxin response in deficient patients

Possible Side Effects

Allergic reaction (rare, usually with IV administration)rare

Tip: Discontinue if symptoms occur

Mild GI upsetrare

Tip: Take with food

Warnings

  • Chronic alcohol use depletes thiamine
  • Deficiency can cause serious neurological problems

Top studies from 40+ peer-reviewed papers

meta-analysisn=3101
DOI

Pattanittum P et al. • The Cochrane database of systematic reviews (2016)

“There is no high quality evidence to support the effectiveness of any dietary supplement for dysmenorrhoea, and evidence of safety is lacking.”
Key Findings:
  • Supplements versus other supplementsThere was no evidence of a difference in effectiveness between ginger and zinc sulphate (MD 0.02 points, 95% CI -0.58 to 0.62; one RCT, 101 women).
  • Vitamin B1 may be more effective than fish oil (MD -1.59 points, 95% CI -2.25 to -0.93; one RCT, 120 women).
  • There is no high quality evidence to support the effectiveness of any dietary supplement for dysmenorrhoea, and evidence of safety is lacking.
  • However for several supplements there was some low quality evidence of effectiveness and more research is justified.
rctn=316
DOI

Harrison CN et al. • The Lancet. Haematology (2024)

“Findings from FREEDOM2 support fedratinib as a second-line Janus kinase inhibitor option to reduce spleen size after ruxolitinib failure or intolerance in patients with myelofibrosis, and shows effective strategies for management of gastrointestinal adverse events and low thiamine concentrations through prophylaxis, monitoring, and treatment.”
Key Findings:
  • Clinical trial examining Thiamine efficacy
  • Published in The Lancet. Haematology (2024)
  • Further research warranted to confirm findings
meta-analysisn=3494
DOI

Nakanishi N et al. • Clinical nutrition (Edinburgh, Scotland) (2024)

“Although thiamine administration may reduce shock state, it may not reduce mortality, and slightly increases the length of ICU stay.”
Key Findings:
  • Conversely, thiamine administration resulted in a slight increase in the length of ICU stay (MD, 0.40 days; 95% CI, 0.01-0.79 days; High CoE).
  • Although thiamine administration may reduce shock state, it may not reduce mortality, and slightly increases the length of ICU stay.
  • Further research warranted to confirm findings
meta-analysisn=2594
DOI

Deng J et al. • International archives of allergy and immunology (2024)

“HAT appears beneficial in reducing vasopressor use and improving organ function in sepsis/septic shock patients.”
Key Findings:
  • At 72 h, HAT reduced SOFA scores from baseline (mean difference [MD] -1.16, 95% confidence interval [CI]: -1.58 to -0.74, I2 = 0%) compared to placebo/SoC, based on moderate quality of evidence.
  • HAT also reduced the duration of vasopressor use (MD -18.80 h, 95% CI: -23.67 to -13.93, I2 = 64%) compared to placebo/SoC, based on moderate quality of evidence.
  • HAT increased hospital LOS (MD 2.05 days, 95% CI: 0.15-3.95, I2 = 57%) compared to placebo/SoC, based on very low quality of evidence.
rctn=122
DOI

Monfort J et al. • Nutrients (2024)

“Regarding pain, however, although there was a numerical improvement, it did not reach statistical significance.”
Key Findings:
  • Both groups showed pain improvement, but the VAS reduction (control: 24.58 vs. experimental: 31.35) was not statistically significant.
  • The Roland Morris score decreased significantly in the experimental group (estimate: -1.70, 95% CI -3.29 to -0.10; p = 0.038), and these patients were 5 times more likely to progress to a better CGI category (OR = 0.20, 95% CI 0.07 to 0.57; p = 0.003).
  • No significant differences were observed in EQ-5D-5L scores or analgesic consumption.
  • Conclusions: The addition of supplemental pyrimidine nucleotides and vitamins B1 and B12 to standard of care treatment improved radiculopathy functional and clinical outcomes.
39
Total Studies
9.1/10
Avg Quality
16-10,257
Sample Size Range
2005-2025
Research Span

Study Type Distribution

Meta-Analysis
15
RCT
14
Systematic Review
10

This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.